|Human, Mouse, Rat|
Application Methods: Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Western Blotting
Background: Neuropeptide Y (NPY) is a 36 amino acid peptide that belongs to the pancreatic polypeptide (PP) family, which also includes peptide YY (PYY) (1). The mature 36-residue NPY is produced from a larger pre-pro 97-residue NPY precursor through a series of cleavage reactions at dibasic sites and C-terminal amidation of the peptide product (2). NPY is widely expressed in the central nervous system (3) and exerts its action through stimulation of 5 different receptors (Y1-Y5) that belong to the G protein-coupled receptor family (4). NPY in the hypothalamus exhibits orexigenic activity through activation of Y1 and Y5 receptors (5). NPY is involved in the control of bone homeostasis, through the regulation of osteoblast activity by Y1 and Y2 receptors (6), and the regulation of testosterone secretion by activating Y1 receptor in testicular vessels (7). Research studies suggest that modulation of NPY activity and signaling represents a potential strategy for the development of appetite control and antiobesity agents (8).
|Human, Mouse, Rat|
Application Methods: Immunofluorescence (Frozen), Immunoprecipitation, Western Blotting
Background: Metabotropic glutamate receptor 2 (mGluR2) is a class C G protein-coupled receptor for the neurotransmitter glutamate in the mammalian brain. Unlike ionotropic receptors, metabotropic receptors do not form an ion channel pore themselves but are indirectly linked to ion channels (1). While mGluR1 and mGluR5 activate phospholipase C, mGluR2, mGluR3, mGluR4, and mGluR6 are coupled to the inhibitory G protein Gα(i/o) and inhibit adenylyl cyclase (AC) activity (1). Research studies have suggested that mGluR2/3 receptors may be potential targets for the treatment of Schizophrenia (2). Furthermore, mGluR2 interacts with the 5HT2A serotonin receptor to form a hetero-complex in the brain. This complex is a potential pharmacological target for hallucinogenic drugs (3,4).